Literature DB >> 10642528

Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase.

C R Chitambar1, J P Wereley, T Heiman, W E Antholine, W J O'brien.   

Abstract

Ribonucleotide reductase is an iron-containing enzyme that is essential for DNA synthesis. Whereas previous studies have used various iron chelators to examine the relationship between cellular iron metabolism and ribonucleotide reductase activity in cells, they have not elucidated the relationship between iron transport into cells and the expression of the gene for ribonucleotide reductase. To investigate this, we examined ribonucleotide reductase mRNA, protein and enzyme activity in a novel line of CCRF-CEM cells (DFe-T cells) that display an approx. 60% decrease in their uptake of iron compared with the parental wild-type cell line. We found that DFe-T cells displayed an approx. 40% decrease in ribonucleotide reductase specific enzyme activity relative to wild-type cells without a change in their proliferation. Kinetic analysis of CDP reductase activity revealed an approx. 60% decrease in V(max) in DFe-T cells without a change in K(m). Despite the decrease in enzyme activity, the mRNA and protein for the R1 and R2 subunits of ribonucleotide reductase in DFe-T cells were similar to those of wild-type cells. ESR spectroscopy studies revealed that DFe-T cells had a 22% decrease in the tyrosyl free radical of the R2 subunit, suggesting that a larger amount of R2 protein was present as functionally inactive apo-R2 in these cells. Our studies indicate that ribonucleotide reductase activity in CCRF-CEM cells can be down-regulated by more than 50% in response to down-regulated iron transport without an adverse effect on cell proliferation. Furthermore, our studies suggest a regulatory link between ribonucleotide reductase activity and iron transport into these cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642528      PMCID: PMC1220804     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  A rapid assay for CDP reductase activity in mammalian cell extracts.

Authors:  J R Steeper; C D Steuart
Journal:  Anal Biochem       Date:  1970-03       Impact factor: 3.365

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits.

Authors:  Y Engström; S Eriksson; I Jildevik; S Skog; L Thelander; B Tribukait
Journal:  J Biol Chem       Date:  1985-08-05       Impact factor: 5.157

4.  Ribonucleotide reductase M2 subunit sequences mapped to four different chromosomal sites in humans and mice: functional locus identified by its amplification in hydroxyurea-resistant cell lines.

Authors:  T L Yang-Feng; D E Barton; L Thelander; W H Lewis; P R Srinivasan; U Francke
Journal:  Genomics       Date:  1987-09       Impact factor: 5.736

5.  Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation.

Authors:  H M Lederman; A Cohen; J W Lee; M H Freedman; E W Gelfand
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

6.  Antineuroblastoma activity of desferoxamine in human cell lines.

Authors:  J Blatt; S Stitely
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

7.  The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse.

Authors:  J E Brissenden; I Caras; L Thelander; U Francke
Journal:  Exp Cell Res       Date:  1988-01       Impact factor: 3.905

8.  Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.

Authors:  C A Sauvage; J C Mendelsohn; J F Lesley; I S Trowbridge
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

Review 9.  Ribonucleotide reductases.

Authors:  A Jordan; P Reichard
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  The tyrosyl free radical in ribonucleotide reductase.

Authors:  A Gräslund; M Sahlin; B M Sjöberg
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

View more
  3 in total

1.  Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.

Authors:  Rajan Gogna; Esha Madan; Bernhard Keppler; Uttam Pati
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

3.  Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy.

Authors:  Nastasia Wilfinger; Shane Austin; Barbara Scheiber-Mojdehkar; Walter Berger; Siegfried Reipert; Monika Praschberger; Jakob Paur; Robert Trondl; Bernhard K Keppler; Christoph C Zielinski; Karin Nowikovsky
Journal:  Oncotarget       Date:  2016-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.